Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 24% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Alexion 2Q Revenues: $636.2 million (+24%) 2Q Earnings: $170.2 million (+2%) YTD Revenue: $1.2 billion (+15%) YTD Earnings: $261.5 million (-20%) Comments: Solirissales were $636 million in the quarter, up 24%. R&D expenses were $131.7 million compared to $92.6 million in 2Q14. The company closed the Synageva acquisition in the quarter, strengthening its rare diseases portfolio. Strensiq received a positive opinion from the EMA recommending marketing authorization for the long...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters